Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 in advanced pancreatic cancer
NCT07301229Phase 2Not yet recruiting
- Sponsor
- Henlius
- Start
- Dec 2025
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of HLX43 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Henlius. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
HLX43
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07301229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07301229.